Skip to main content

Table 1 Patient Characteristics

From: Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000

  Cohort A
(n = 170)
Cohort B
(n = 237)
Total
(n = 407)
Characteristic No. of Patients % No. of Patients % No. of Patients %
Median age, years 51.0 53.8 52.6
T stage       
   T1-T2 126 74.1 178 75.1 304 74.7
   T3-T4 40 23.5 51 21.5 91 22.4
   Unknown 4 2.4 8 3.4 12 2.9
No. of axillary nodes involved       
   ≤3 nodes 96 56.5 139 58.6 235 57.7
   >3 nodes 70 41.2 80 33.8 150 36.9
   Unknown 4 2.4 8 3.4 12 2.9
Hormonal status       
   Negative 75 44.1 70 29.5 145 35.6
   Positive 95 55.9 167* 70.5 262 64.4
HER-2 status       
   Negative 126 74.1 177 74.7 303 74.4
   Positive 44 25.9 60 25.3 104 25.6
Subtype       
   HR + and HER-2 - 72 42.4 133* 56.1 205 50.4
   HR + and HER-2 + 23 13.5 34 14.3 57 14.0
   HR - and HER-2 + 21 12.4 26 11.0 47 11.5
   HR - and HER-2 - 54 31.8 44* 18.6 98 24.1
Relapse Free Interval       
   ≤ 2 yr 81 47.6 84* 35.4 165 40.5
   >2 yr 89 52.4 153 64.6 242 59.5
Site of first recurrence       
   non visceral 77 45.3 124 52.3 201 49.4
   visceral 93 54.7 113 47.7 206 50.6
Brain metastasis at diagnosis       
   no 163 95.9 224 94.5 387 95.1
   yes 6 3.5 12 13.0 18 4.4
Adjuvant chemotherapy       
   no 59 34.7 65 27.4 124 30.5
   yes 111 65.3 172 72.6 283 69.5
Adjunvant endocrine therapy       
   no 80 47.1 92 38.8 172 42.3
   yes 90 52.9 145 61.2 235 57.7
  1. *P < .05
  2. Abbreviations: HR, hormone receptor; HER-2, human epidermal growth factor receptor 2